🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Singapore / NCT07176130
Active, not recruiting Observational

Demographics and Clinical Characteristics of Ocular Inflammatory Diseases in Singapore

NCT07176130 · tracked via the Priya Life Science Singapore tracker
Phase
Observational
Started
2025-08-19
Last updated
2025-09-16

Condition(s) studied

UveitisScleritis and EpiscleritisEndophthalmitisMasquerade SyndromesIntraocular Lymphoma

Investigational drug(s) / intervention(s)

No Intervention: Observational Cohort

No Intervention: Observational Cohort: Not applicable, No intervention. Observational study.

Study summary

This is a retrospective study analyzing demographics, clinical characteristics, treatment received, and outcomes of ocular inflammatory diseases that presented to the Singapore National Eye Centre (SNEC).

Eligibility

Sex
ALL
Min age
21 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria: * Patients diagnosed with uveitis * Patients diagnosed with scleritis or episcleritis * Patients diagnosed with ocular neoplasms e.g., vitreoretinal and uveal lymphoma * Patients diagnosed with endophthalmitis * Diagnosis confirmed by laboratory testing or histopathological examination * Patients diagnosed and managed at the Singapore National Eye Centre (SNEC) Exclusion Criteria: * Patients with less than two years of clinical follow-up * Patients with incomplete diagnostic confirmation (i.e., lacking laboratory or histopathological evidence) * Patients diagnosed outside of Singapore National Eye Centre (SNEC) * Cases with missing key clinical or outcome data

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Singapore National Eye Centre Singapore Singapore

More Singapore National Eye Centre trials in Singapore

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07176130 on ClinicalTrials.gov ↗ ← All trials in Singapore